论文部分内容阅读
由于大输液在临床上的用量日益增加,对其质量要求也日趋提高,药液中的微粒污染(因50μm以下的微粒人的肉眼看不出),给病人带来危害,轻者局部发炎,肿痛。重者引起肺、肾等组织微血管肉芽瘤。因此,许多国家药典对此已作出规定。例如BP(80版)规定每毫升含2μm或2μm以上的粒子不得多于1000个,5μm或5μm以上的微粒不得多于100个;USP XX版NFXV及JPX规定每毫升含10μm以上的微粒不得超过50个;25μm以上的微粒不得超过5个。为了达到
Due to the large infusion in the clinical dosage is increasing, the quality requirements are also increasing, the liquid in the particulate pollution (due to 50μm or less particles of the human eye can not see), to the patient harm, light local inflammation, Sore and painful. Severe cases of lung, kidney and other organizations microvascular granuloma. Therefore, many national pharmacopoeias have made provisions for this. For example, BP (80th edition) stipulates that no more than 1000 particles of 2μm or more per milliliter and no more than 100 particles of 5μm or more; USP XX NFXV and JPX shall not exceed 10μm per milliliter 50; 25μm above the particles shall not exceed 5. In order to achieve